Medtronic reported a strong quarter with 6% organic growth, led by 80% growth in its cardiovascular portfolio, particularly pulsed field ablation (PFA). Management reiterated fiscal 2026 guidance but expressed confidence in accelerated growth in FY27, driven by a broad pipeline including renal denervation (Simplicity), tibial nerve stimulation (AltaViva), Hugo surgical robot, and new neuroscience platforms. Key theme is the scaling of multiple new product launches into U.S. markets. Reported Q3 FY26 revenue of $9.0B (+6% organic) and EPS of $1.36, beating guidance on revenue but noting tax pressure.
Medtronic reported a strong quarter with 6% organic growth, led by 80% growth in its cardiovascular portfolio, particularly pulsed field ablation (PFA). Management reiterated fiscal 2026 guidance but expressed confidence in accelerated growth in FY27, driven by a broad pipeline including renal denervation (Simplicity), tibial nerve stimulation (AltaViva), Hugo surgical robot, and new neuroscience platforms. Key theme is the scaling of multiple new product launches into U.S. markets. Reported Q3 FY26 revenue of $9.0B (+6% organic) and EPS of $1.36, beating guidance on revenue but noting tax pressure.
Management conveyed strong optimism about growth drivers, pipeline breadth, and accelerating growth, highlighted by phrases like 'we feel good about that acceleration' and 'we are confident in our ability to deliver durably.'
Reported Q3 FY26 revenue of $9.0B (+6% organic) and EPS of $1.36, beating guidance on revenue but noting tax pressure.
PFA (cardiac ablation) grew 80% YoY, with the company highlighting a strong competitive position with its Sphere-9 and Sphere-360 catheters.
RDN driving 50x increase in website visits from DTC campaign. Management conveyed strong optimism about growth drivers, pipeline breadth, and accelerating growth, highlighted by phrases like 'we feel good about that acceleration' and 'we are confident in our ability to deliver…
Management highlighted AI-powered technologies such as the Stealth Access surgical system (unifying AI power planning, robotics, and navigation) and the TouchSurgery digital ecosystem, emphasizing their differentiation and growth potential, though specific AI revenue or adoption metrics were limited.
RDN driving 50x increase in website visits from DTC campaign. Management conveyed strong optimism about growth drivers, pipeline breadth, and accelerating growth, highlighted by phrases like 'we feel good about that acceleration' and 'we are confident in our ability to deliver durably.'
Capex not specifically discussed. Management referenced investments in R&D, M&A, and direct-to-consumer marketing to support growth drivers.
Management conveyed strong optimism about growth drivers, pipeline breadth, and accelerating growth, highlighted by phrases like 'we feel good about that acceleration' and 'we are confident in our ability to deliver durably.'
“last quarter we had maybe 50,000, or Q2 rather, we had about 50,000 visits. In Q3, we had 2.5 million visits.”
“hiring mappers has been critical... it is the thing that we're probably the most focused on right now is continuing to hire mappers.”
“Stealth Access was designed around navigation, which is paramount to surgeons' workflow in the OR”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $5.62–$5.66 | $5.64 | MAINTAINED |
| EPS | FY2027 | 7%–9% | 8% | MAINTAINED |
| Revenue | FY2026 | 5.5% | 5.5% | MAINTAINED |
Medtronic's renal denervation (Simplicity) direct-to-consumer website visits jumped from 50,000 to 2.5 million quarter-over-quarter, indicating significant patient demand and market development traction. — This early consumer demand signal suggests the RDN market could develop faster than expected, benefiting Medtronic and pressuring competitors like Boston Scientific.
Good morning, everyone. Thank you so much for taking the question. Jeff, I was hoping you could talk a little bit more about how we should think about renal denervation simplicity and the market development that you're talking about. You know, we've talked to some referring physicians who've been involved in renal denervation since the very beginning, and she sounds like she's getting a lot of calls from folks. I'm just curious, what goes into actually developing this market, building out, helping centers build out referral networks, et cetera? And if you could give any color on actual numbers to date, you know, even directionally. Thanks so much.
Sorry about that. Sure. Thanks, Danielle. I mean, I appreciate that question. I mean, you know, first of all, in terms of physicians getting a lot of calls, That is really starting to kick in. Just to give you, again, I appreciate that it's a leading indicator, but it's pretty powerful. So on our direct-to-consumer website around simplicity, I'm just double-checking, last quarter we had maybe 50,000, or Q2 rather, we had about 50,000 visits. In Q3, we had 2.5 million visits. So the consumer demand is really spiking here, and we're just getting started. Like I said earlier, we opened up over 200 accounts. The position finder is up. Reimbursement is strong. We're getting that strong consumer demand. And most importantly, we're getting terrific results. patient results, patient outcomes, right, with the blood pressure coming down meaningfully, it's staying, and it's really resonating with patients. And that, in and of itself, is getting doctors excited. And so what we're doing is we've been hiring a lot of people in terms of market development. And there's several different roles here, right? One is building that referral pathway from the general practitioners and the hypertensive specialists into the hospital, into that procedural list, We've got a lot of people around health economics, around coding and billing as well, helping the hospitals. So it's a number of roles like that, right, health economics, coding, billing, as well as some of the other roles I said in terms of the market development, building those referral pathways. And that's really where things are right now. I'd say all the market, like the initial foundational elements have all been, like, The chips have turned over green, right? The FDA approval is breakthrough approval, and it's broad. The CMS reimbursement, it's a good number, and it's broad. You know, the commercial payers are, you know, falling in line. And, you know, the competitive dynamics are way better than we thought. Initially here we're doing – I saw different analysts, you know, over the last couple of years, predictions on the mix between us and the other competitor on the market. We're doing way better than any of those models. And so now we've just got to build this market. It's all those things we said, Danielle. But, again, where we're really excited, where you feel the energy, is it all starts with those patient outcomes …
Medtronic's new Stealth Access spinal surgery system is a new platform designed to integrate with the 70% of US spine procedures that are currently navigated, lowering barriers to robotics adoption. — By leveraging its dominant navigation install base (10,000 units), Medtronic could significantly accelerate robotics adoption in spine surgery, challenging competitors like Stryker and Intuitive Surgical.
… coronary DCB, cardiac rhythm management, spine surgery, as well as many others. And to that point, I am extremely excited to highlight a major milestone in our neuroscience business. Just last week, we secured FDA clearance for our Stealth Access surgical system for spinal procedures. Stealth Access is a new transformative platform that unifies AI power planning, robotics, and navigation into one seamless system, elevated by the entire ABLE ecosystem. Stealth access was designed around navigation, which is paramount to surgeons' workflow in the OR. Today, navigation, which we pioneered and we lead, drives 70% of U.S. spine procedures, and really, it just dictates the workflow in the spine OR. So stealth is really two things. It's about taking share as a new platform with improved functionality, and it brings down barriers for physicians to step into robotics without disrupting their workflow. Now, building on our 10,000-unit installed base, we are expanding and opening this segment and extending our leadership. And we're not stopping at spine. We anticipate pursuing future cranial and ENT indications for stealth access. This is an important driver for our CST business and …